CSL
Search    
Include All CSL Behring Country Sites

Press Releases

12/22/2008
CSL Biotherapies Announces Influenza Vaccine Pre-Booking Open for the 2009-2010 Flu Season
CSL Biotherapies, a subsidiary of one of the world’s leading manufacturers of influenza vaccine, today announced that healthcare providers now have the opportunity to pre-book the company’s influenza virus vaccine through either www.mercuryfreefluvaccine.com or the toll-free number, 1-888-435-8633. The majority of CSL Biotherapies’ vaccine supply for the 2009-2010 flu season will be offered as thimerosal-free, single-dose, pre-filled syringes. To help increase access to the thimerosal-free vaccine, CSL Biotherapies will offer value programs for a limited time to healthcare providers who pre-book through authorized distributors. More.

11/14/2008
Jesse Palmer Throws a "Season Pass" at Influenza Awareness to College Students Nationwide
To increase flu vaccination rates among college students, CSL Biotherapies is partnering on Season Pass© with Jesse Palmer, ESPN co-host of "College Football Live" and former pro football player. Season Pass is a novel program designed to immunize as many college students as possible during the 2008-2009 influenza (flu) season. College students are at risk for contracting the flu due to their close living quarters and frequent contact with other students. Season Pass aims to educate college students about influenza prevention and motivate them to visit their on-campus health center to get vaccinated. More.

10/16/2008
CSL Biotherapies Launches www.mercuryfreefluvaccine.com, An Online, Order-As-You-Go Service for Thimerosal-Free Influenza Vaccine
CSL Biotherapies, a subsidiary of one of the world's leading manufacturers of influenza vaccine, today announced an innovative online quick-ship ordering system, enabling healthcare providers and other purchasers to buy CSL Biotherapies' thimerosal-free flu vaccine for adults directly from the company. This new purchasing platform (accessible at www.mercuryfreefluvaccine.com) offers customers enhanced access to a thimerosal-free product in the quantity they need, whenever they need it. More.

09/04/2008
CSL Biotherapies Announces First Shipments of Afluria® Thimerosal-Free Influenza Vaccine for the 2008-2009 Flu Season
CSL Biotherapies, a subsidiary of one of the world's leading manufacturers of influenza vaccine, announced today that it has begun shipment of its influenza virus vaccine in the U.S. for the 2008-2009 season. CSL plans to deliver more than six million doses of Afluria and the majority of the supply will be in single-dose, thimerosal-free, pre-filled syringes. More.

05/13/2008
CSL Marks 40 Years in the Influenza Vaccine Market
CSL Limited today celebrated its 40th year as a leading manufacturer of influenza (flu) vaccine.  The company’s vaccine, Fluvax®, is a Thiomersal-free influenza vaccine that is approved for use in adults and children in Australia and New Zealand.  This vaccine is known as Afluria™, Enzira™, Nilgrip™, and X-Flu™ in 17 different countries, including the US and European markets.  Additionally, CSL supplies the antigen used to manufacture the flu vaccine in 24 countries.  More.

04/03/2008
CSL Biotherapies Announces Afluria® Pre-Booking Open
CSL Biotherapies announced today that healthcare providers now have the opportunity to pre-book Afluria® (influenza virus vaccine) through either www.afluria.com or at the company’s toll-free number 1-888-435-8633. CSL Biotherapies, which entered the U.S. market last season, plans to produce approximately 6 million doses of Afluria for delivery in time for the upcoming season. The majority of the Afluria supply for the upcoming season will be in single-dose, thimerosal-free, pre-filled syringes. More.

10/17/2007
CSL Biotherapies Starts U.S. Shipments of Influenza Vaccine
CSL Biotherapies, a subsidiary of one of the world's leading manufacturers of influenza vaccine, announced today that it has begun shipment of its influenza virus vaccine in the United States for the 2007-2008 season. More.

09/28/2007
CSL Biotherapies announces FDA marketing approval of Afluria®
Global biopharmaceutical company with strong vaccine heritage affirms commitment to help address critical U.S. public health need More.

08/01/2007
CSL to Build High-Speed Syringe Fill Line at its Kankakee (Il) Facility
CSL Behring today announced plans to invest $15 million to expand its manufacturing facility here by adding a high-speed, single-dose syringe filling line. Plans call for the line to be operational in 2010, when the company intends to contract with its sister company, CSL Biotherapies, to provide filling and packaging services for seasonal influenza vaccine. More.

06/05/2006
CSL Biotherapies, A New Entrant Into U.S. Flu Market, Starts Influenza Vaccine Biological Licensure Trial
Enrollment will begin for a pivotal influenza vaccine clinical trial sponsored by the National Institutes of Health (NIH), CSL Biotherapies announced today. The study will assess the safety and immunogenicity of single-dose and multi-dose formulations of influenza vaccine and has been designed to meet U.S. Food & Drug Administration (FDA) requirements. More.

02/07/2006
CSL Limited to Apply for License to Market Influenza Vaccine in the U.S.
CSL Limited (ASX: CSL), a global, specialty biopharmaceutical company headquartered in Melbourne, Australia, today announced plans to introduce its influenza vaccine into the U.S. market. More.